Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Calidi Biotherapeutics Inc (CLDI)

Calidi Biotherapeutics Inc (CLDI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,440
  • Shares Outstanding, K 13,078
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,220 K
  • EBIT $ -40 M
  • EBITDA $ -38 M
  • 60-Month Beta 1.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2700 +14.17%
on 12/20/24
2.3025 -37.02%
on 11/27/24
-0.6900 (-32.24%)
since 11/22/24
3-Month
0.7300 +98.63%
on 10/25/24
3.8900 -62.72%
on 11/13/24
+0.2700 (+22.88%)
since 09/24/24
52-Week
0.7300 +98.63%
on 10/25/24
16.9000 -91.42%
on 12/26/23
-15.2500 (-91.32%)
since 12/22/23

Most Recent Stories

More News
Calidi Biotherapeutics (NYSE American: CLDI) at the Forefront of Cancer Treatment Innovation

Calidi Biotherapeutics (NYSE American: CLDI) was featured in a recent article that showcased the company as a compelling example of progress of emerging therapies and advances that are reshaping the fight...

CLDI : 1.4500 (+2.84%)
Calidi Biotherapeutics (NYSE American: CLDI) Data Demonstrates Potential of Innovative Solutions to Revolutionize Cancer Care

Cancer continues to be a leading cause of morbidity and mortality worldwide, affecting millions of lives every year. While advances in prevention, early detection and treatment have made strides in reducing...

CLDI : 1.4500 (+2.84%)
Calidi Biotherapeutics (NYSE American: CLDI) Shares Data Supporting Proprietary Systemic Antitumor Platform

T he American Cancer Society (“ACA”) has projected that 2024 will be the first year ever to see two million people diagnosed with cancer, which remains the second leading cause of death in the United...

CLDI : 1.4500 (+2.84%)
Calidi Biotherapeutics (NYSE American: CLDI) Raises $7.5 Million Through Public Stock Offering

Calidi Biotherapeutics (NYSE American: CLDI) announced the successful closing of a public offering of 4,437,869 shares of common stock at $1.69 per share, raising approximately $7.5 million in gross proceeds....

CLDI : 1.4500 (+2.84%)
Calidi Biotherapeutics (NYSE American: CLDI) Showcases RTNova Virotherapy Breakthrough

Calidi Biotherapeutics (NYSE American: CLDI) presented data at the International Oncolytic Virotherapy Conference and the Society for Immunotherapy of Cancer Annual Meeting highlighting its RTNova systemic...

CLDI : 1.4500 (+2.84%)
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

CLDI : 1.4500 (+2.84%)
Calidi Biotherapeutics Inc. Completes Public Offering, Raising Approximately $7.5 Million

Calidi Biotherapeutics closed a public offering of approximately 4.4 million shares, raising $7.5 million for its cancer therapies.Quiver AI SummaryCalidi Biotherapeutics Inc. has successfully closed a...

CLDI : 1.4500 (+2.84%)
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

CLDI : 1.4500 (+2.84%)
Calidi Biotherapeutics (NYSE American: CLDI) Announces Public Offering

Calidi Biotherapeutics (NYSE American: CLDI) has announced plans to sell shares of its common stock and/or pre-funded warrants in a public offering with Ladenburg Thalmann & Co. Inc. as the exclusive placement...

CLDI : 1.4500 (+2.84%)
Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

CLDI : 1.4500 (+2.84%)

Business Summary

Calidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer with a novel stem cell-based therapy. Calidi Biotherapeutics Inc., formerly known as First Light Acquisition Group, is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 1.6567
2nd Resistance Point 1.5533
1st Resistance Point 1.5017
Last Price 1.4500
1st Support Level 1.3467
2nd Support Level 1.2433
3rd Support Level 1.1917

See More

52-Week High 16.9000
Fibonacci 61.8% 10.7231
Fibonacci 50% 8.8150
Fibonacci 38.2% 6.9069
Last Price 1.4500
52-Week Low 0.7300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar